AZN GB0009895292

Report

Delayed London Stock Exchange - 12/02 11:35:18 am
8231	GBX		-1.00%

12:29p	What COVID-19 vaccine and drug makers have to say about Omicron	RE
12/01	Scientists Discover Cause Behind Blood Clot Formation After AstraZeneca Vaccine	MT
12/01	Abbisko Unit Doses First Patient in China Phase II Trial of Urothelial Cancer Therapy	MT

Company

Business Summary

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Number of employees : 76 100 people.

Sales per Business

	2019		2020		Delta
Oncology	6 793.71	35.5%	8 461.00	39.3%	+24.54%
Cardiovascular, Renal & Metabolism	5 413.33	28.3%	5 533.57	25.7%	+2.22%
Respiratory	4 225.79	22.1%	4 177.47	19.4%	-1.14%
Other Diseases	2 038.82	10.7%	2 017.38	9.4%	-1.05%
Externalisation Revenue	641.98	3.4%	566.93	2.6%	-11.69%
GBP in Million

Sales per region

	2019		2020		Delta
United States	6 307.72	33%	6 983.25	32.5%	+10.71%
China	3 815.04	20%	4 168.11	19.4%	+9.25%
Japan	1 976.89	10.3%	2 001.79	9.3%	+1.26%
United Kingdom	1 428.19	7.5%	1 357.66	6.3%	-4.94%
Other Asia, Africa and Australasia	1 111.51	5.8%	1 196.24	5.6%	+7.62%
Other Continental Europe	1 011.96	5.3%	1 084.72	5%	+7.19%
Sweden	653.74	3.4%	800.09	3.7%	+22.39%
Germany	551.84	2.9%	730.69	3.4%	+32.41%
Other Americas	638.06	3.3%	593.44	2.8%	-6.99%
France	453.07	2.4%	509.22	2.4%	+12.39%
Canada	365.28	1.9%	464.77	2.2%	+27.24%
Italy	310.41	1.6%	336.10	1.6%	+8.28%
Spain	281.41	1.5%	310.37	1.4%	+10.29%
Australia	208.51	1.1%	219.91	1%	+5.47%
GBP in Million

Managers

Name	Title	Age	Since
Pascal Soriot	Chief Executive Officer & Executive Director	61	2012
Aradhana Sarin	Chief Financial Officer & Executive Director	46	2021
Menelas Pangalos	EVP-Biopharmaceuticals Research & Development	53	2019
Pam Cheng	Executive VP-Operations & Information Technology	49	2015
Henry Cremisi	Medical Director	-	-
Hasan Jafri	Senior Medical Director	-	-
Katarina Ageborg	Chief Compliance Officer & EVP-Sustainability	-	2017
Marcus Wallenberg	Independent Non-Executive Director	64	1999
Leif Johansson	Non-Executive Chairman	69	2012
Philip Arthur John Broadley	Senior Independent Non-Executive Director	59	2021

Members of the board

Name	Title	Age	Since
Leif Johansson	Non-Executive Chairman	69	2012
Marcus Wallenberg	Independent Non-Executive Director	64	1999
Pascal Soriot	Chief Executive Officer & Executive Director	61	2012
Philip Arthur John Broadley	Senior Independent Non-Executive Director	59	2021
Nazneen Rahman, Dr.	Independent Non-Executive Director	-	2017
Sherilyn McCoy	Independent Non-Executive Director	61	2017
Deborah DiSanzo	Independent Non-Executive Director	60	2017
Tony Mok, Dr.	Independent Non-Executive Director	59	2019
Michel Demaré	Independent Non-Executive Director	65	2019
Euan A. Ashley, Dr.	Non-Executive Director	-	2020

Equities

	Vote	Quantity	Free-Float		Company-owned shares		Total Float
Stock A	1	1,549,158,964	1,492,933,845	96.4%	0	0.0%	96.4%

Shareholders

Name	Equities	%
Wellington Management Co. LLP	68,525,329	4.42%
Capital Research & Management Co. (World Investors)	56,102,804	3.62%
BlackRock Investment Management (UK) Ltd.	54,582,684	3.52%
Investor AB (Investment Company)	51,587,810	3.33%
The Vanguard Group, Inc.	43,410,000	2.80%
Norges Bank Investment Management	29,430,000	1.90%
BlackRock Fund Advisors	26,594,541	1.72%
Capital Research & Management Co. (Global Investors)	20,726,848	1.34%
BlackRock Advisors (UK) Ltd.	19,081,467	1.23%
SSgA Funds Management, Inc.	14,043,000	0.91%

Holdings

Name	Equities	%	Valuation
ASTRAZENECA PHARMA INDIA LIMITED (506820)	18,750,000	75.0%	753,155,063 USD
ADC THERAPEUTICS SA (ADCT)	4,011,215	5.23%	116,285,123 USD
CIRCASSIA GROUP PLC (CIR)	71,081,217	17.0%	41,896,691 USD
INNATE PHARMA (IPH)	7,485,500	9.48%	41,857,643 USD
SILENCE THERAPEUTICS PLC (SLNCF)	4,397,247	4.90%	30,439,019 USD
PIERIS PHARMACEUTICALS, INC. (PIRS)	3,584,230	5.37%	16,415,773 USD
PHASEBIO PHARMACEUTICALS, INC. (PHAS)	3,004,554	6.25%	11,297,123 USD
INOZYME PHARMA, INC. (INZY)	1,109,910	4.69%	10,366,559 USD
ENTASIS THERAPEUTICS HOLDINGS INC. (ETTX)	2,164,855	4.58%	6,169,837 USD
ARIDIS PHARMACEUTICALS, INC. (ARDS)	884,956	7.30%	3,097,346 USD

Markets and indexes

- Main Market

- OMX Stockholm 30 / FTSE 100, FTSE 350, FTSE All-Share, FTSE Eurotop 100, Low Carbon 100 Europe, NASDAQ OMX Nordic 120, OMX Nordic 40, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200, Stoxx UK 50

Stock Exchange Codes


- Bloomberg Code :	AZN:LN
- Reuters Code :	AZN.L
- Datastream Code :	AZN

Company contact information

AstraZeneca PLC
Cambridge Biomedical Campus 1 Francis Crick Avenue
CB2 0AA Cambridge, Cambridgeshire

Phone : +44 (0)20 3749 5000
Fax : +44 (0)20 7604 8151
web site : https://www.astrazeneca.com/investor-relations.html